In the last trading session, 2.09 million shares of the RAPT Therapeutics Inc (NASDAQ:RAPT) were traded, and its beta was 0.02. Most recently the company’s share price was $1.62, and it changed around -$0.07 or -4.14% from the last close, which brings the market valuation of the company to $52.88M. RAPT currently trades at a discount to its 52-week high of $27.35, offering almost -1588.27% off that amount. The share price’s 52-week low was $0.79, which indicates that the current value has risen by an impressive 51.23% since then. We note from RAPT Therapeutics Inc’s average daily trading volume that its 10-day average is 16.24 million shares, with the 3-month average coming to 3.08 million.
RAPT Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 7 recommended RAPT as a Hold, whereas 2 deemed it a Buy, and 1 rated it as Underweight. RAPT Therapeutics Inc is expected to report earnings per share of -0.22 for the current quarter.
RAPT Therapeutics Inc (NASDAQ:RAPT) trade information
Instantly RAPT has showed a red trend with a performance of -4.14% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.3200 on recent trading dayincreased the stock’s daily price by 30.17%. The company’s shares are currently down -93.48% year-to-date, but still up 96.27% over the last five days. On the other hand, RAPT Therapeutics Inc (NASDAQ:RAPT) is 31.71% up in the 30-day period. We can see from the shorts that 1.72 million shares have been sold at a short interest cover period of 3.08 day(s).
The consensus price target as assigned by Wall Street analysts is $2, which translates to bulls needing to increase their stock price by 19.0% from its current value. Analyst projections state that RAPT is forecast to be at a low of $2 and a high of $2.
RAPT Therapeutics Inc (RAPT) estimates and forecasts
RAPT Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -43.75 percent over the past six months and at a 6.23% annual growth rate that is well below the industry average of 16.70%.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.39%.
RAPT Dividends
RAPT Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
RAPT Therapeutics Inc (NASDAQ:RAPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.84% of RAPT Therapeutics Inc shares, and 83.96% of them are in the hands of institutional investors. The stock currently has a share float of 85.53%. RAPT Therapeutics Inc stock is held by 144.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 13.5546% of the shares, which is about 5.24 million shares worth $15.97 million.
VANGUARD GROUP INC, with 8.0472% or 3.11 million shares worth $9.48 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
